These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 15350353)

  • 1. A novel retinoid, 4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid (TAC-101), induces apoptosis of human ovarian carcinoma cells and shows potential as a new antitumor agent for clear cell adenocarcinoma.
    Suzuki N; Aoki D; Oie S; Horiuchi M; Hasegawa Y; Ezawa S; Suzuki A; Susumu N; Hosoi F; Kitazato K; Nozawa S
    Gynecol Oncol; 2004 Sep; 94(3):643-9. PubMed ID: 15350353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A synthetic retinoid, TAC-101 (4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid), plus cisplatin: potential new therapy for ovarian clear cell adenocarcinoma.
    Ezawa S; Suzuki N; Ohie S; Higashiguchi A; Hosoi F; Kitazato K; Susumu N; Aoki D
    Gynecol Oncol; 2008 Mar; 108(3):627-31. PubMed ID: 18048092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The induction of apoptosis and inhibition of AP-1 activity by TAC-101 (4-[3,5-bis(trimethylsilyl) benzamido] benzoic acid) may result in life prolonging effect in animals bearing metastasizing cancer.
    Shibata J; Murakami K; Aoyagi Y; Oie S; Hashimoto A; Suzuki K; Sano M; Wierzba TT; Yamada Y
    Anticancer Res; 2000; 20(5B):3583-90. PubMed ID: 11131666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) induces apoptosis in colon cancer partially through the induction of Fas expression.
    Sako T; Nakayama Y; Minagawa N; Inoue Y; Onitsuka K; Katsuki T; Tsurudome Y; Shibao K; Hirata K; Nagata N; Ohie S; Kohno K; Itoh H
    In Vivo; 2005; 19(1):125-32. PubMed ID: 15796164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 4- [3,5-bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) induced fas expression and activated caspase-3 and -8 in a DLD-1 colon cancer cell line.
    Inoue Y; Nakayama Y; Sako T; Minagawa N; Abe Y; Nagato M; Kadowaki K; Katsuki T; Matsumoto K; Tsurudome Y; Shibao K; Hirata K; Nagata N
    In Vivo; 2007; 21(2):381-7. PubMed ID: 17436592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) inhibits the intrahepatic spread of hepatocellular carcinoma and prolongs the life-span of tumor-bearing animals.
    Murakami K; Matsuura T; Sano M; Hashimoto A; Yonekura K; Sakukawa R; Yamada Y; Saiki I
    Clin Exp Metastasis; 1998 Oct; 16(7):633-43. PubMed ID: 9932610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of AP-1 interference induced by TAC-101 to tumor growth suppression in a hepatocellular carcinoma model.
    Eshima K; Fukaya S; Sugimoto A; Mori T; Yokoi H; Yamamoto Y; Sugiura S; Honda S; Masuko N; Murakami K; Yamasaki Y; Kagechika H
    Tumour Biol; 2009; 30(1):1-7. PubMed ID: 19142034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of cell-cycle arrest and apoptosis by a novel retinobenzoic-acid derivative, TAC-101, in human pancreatic-cancer cells.
    Fujimoto K; Hosotani R; Doi R; Wada M; Lee JU; Koshiba T; Miyamoto Y; Tsuji S; Nakajima S; Imamura M
    Int J Cancer; 1999 May; 81(4):637-44. PubMed ID: 10225456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of 4-[3,5-bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) on the liver metastasis of colon 26-L5 carcinoma cells.
    Sakukawa R; Murakami K; Ikeda T; Yamada Y; Saiki I
    Oncol Res; 1998; 10(6):287-93. PubMed ID: 9848099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TAC-101 (4-[3,5-bis(trimethylsilyl)benzamido]benzoic acid) inhibits spontaneous mediastinal lymph node metastasis produced by orthotopic implantation of Lewis lung carcinoma.
    Murakami K; Yamaura T; Suda K; Ohie S; Shibata J; Toko T; Yamada Y; Saiki I
    Jpn J Cancer Res; 1999 Nov; 90(11):1254-61. PubMed ID: 10622538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
    Chan KK; Wong OG; Wong ES; Chan KK; Ip PP; Tse KY; Cheung AN
    Int J Cancer; 2018 Sep; 143(6):1456-1469. PubMed ID: 29663364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Checkpoint kinase inhibitor AZD7762 overcomes cisplatin resistance in clear cell carcinoma of the ovary.
    Itamochi H; Nishimura M; Oumi N; Kato M; Oishi T; Shimada M; Sato S; Naniwa J; Sato S; Kudoh A; Kigawa J; Harada T
    Int J Gynecol Cancer; 2014 Jan; 24(1):61-9. PubMed ID: 24362713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Anti-tumor Effect of Cabozantinib on Ovarian Clear Cell Carcinoma
    Nakatani M; Watari H; Mitamura T; Wang L; Hatanaka Y; Hatanaka KC; Honda K; Nomura T; Nishihara H; Tanaka S; Sakuragi N
    Anticancer Res; 2017 Nov; 37(11):6125-6132. PubMed ID: 29061793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticancer effect of 4-[3,5-bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) against A549 non-small cell lung cancer cell line is related to its anti-invasive activity.
    Shibata J; Murakami K; Wierzba K; Aoyagi Y; Hashimoto A; Sano M; Toko T; Yamada Y
    Anticancer Res; 2000; 20(5A):3169-76. PubMed ID: 11062739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma.
    Kim HJ; Yoon A; Ryu JY; Cho YJ; Choi JJ; Song SY; Bang H; Lee JS; Cho WC; Choi CH; Lee JW; Kim BG; Bae DS
    Sci Rep; 2016 Dec; 6():38502. PubMed ID: 27917934
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Kawahara N; Yamada Y; Kobayashi H
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53.
    Makii C; Oda K; Ikeda Y; Sone K; Hasegawa K; Uehara Y; Nishijima A; Asada K; Koso T; Fukuda T; Inaba K; Oki S; Machino H; Kojima M; Kashiyama T; Mori-Uchino M; Arimoto T; Wada-Hiraike O; Kawana K; Yano T; Fujiwara K; Aburatani H; Osuga Y; Fujii T
    Oncotarget; 2016 Nov; 7(46):75328-75338. PubMed ID: 27659536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TAC-101, a benzoic acid derivative, inhibits liver metastasis of human gastrointestinal cancer and prolongs the life-span.
    Murakami K; Wierzba K; Sano M; Shibata J; Yonekura K; Hashimoto A; Sato K; Yamada Y
    Clin Exp Metastasis; 1998 May; 16(4):323-31. PubMed ID: 9626811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary.
    Sasano T; Mabuchi S; Kuroda H; Kawano M; Matsumoto Y; Takahashi R; Hisamatsu T; Sawada K; Hashimoto K; Isobe A; Testa JR; Kimura T
    Mol Cancer Res; 2015 Apr; 13(4):795-806. PubMed ID: 25519148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained effect of continuous treatment with bevacizumab following bevacizumab in combination with chemotherapy in a human ovarian clear cell carcinoma xenograft model.
    Ishikura N; Yorozu K; Kurasawa M; Yanagisawa M; Sugimoto M; Yamamoto K
    Oncol Rep; 2019 Sep; 42(3):1057-1065. PubMed ID: 31322247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.